STAT

DECEMBER 17, 2023

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021. Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive.

299

299

Med Ed 101

DECEMBER 17, 2023

Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls related to semaglutide overdose — an increase of over 1500% since 2019 according to a […] The post Semaglutide Overdose – What Does It Look Like and Why Is It Happening?

Diabetes 105

Diabetes 105

STAT

DECEMBER 17, 2023

Every year, the health care industry behaves more and more like a balloon: Squeeze one side, and the other expands. Companies that were once just insurers or just pharmacies are tacking on new business lines. The idea is that when profit inevitably gets squeezed in one, it’ll expand in another. That trend of vertical integration was on full display in 2023, a year when the country’s biggest pharmacy chain bought a primary care provider, and the biggest private insurer branched furt

Hospitals 284

Hospitals 284

pharmaphorum

DECEMBER 17, 2023

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.

94

94

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Guardian - Pharmaceutical Industry

DECEMBER 17, 2023

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January A “gamechanging” drug that prevents hot flushes and could benefit hundreds of thousands of women has been approved for use in the UK. The green light for Veoza, also known as fezolinetant, comes after the US regulator, the Food and Drug Administration, authorised it for use in America in May.

99

99

Drug Patent Watch

DECEMBER 17, 2023

Dasatinib is the generic ingredient in two branded drugs marketed by Apotex and Bristol Myers Squibb and is included in three NDAs. There are two patents protecting this compound. Drug… The post New tentative approval for Teva Pharms drug dasatinib appeared first on DrugPatentWatch - Make Better Decisions.

Compounding 59

Compounding 59

Drug Patent Watch

DECEMBER 17, 2023

Icosapent ethyl is the generic ingredient in two branded drugs marketed by Apotex, Dr Reddys, Hikma, Strides Pharma, Teva Pharms Usa, Zydus, and Amarin Pharms and, and is included in… The post New tentative approval for Ascent Pharms drug icosapent ethyl appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmacy Joe

DECEMBER 17, 2023

In this episode, I’ll discuss the bioavailability of methadone. Episode 879: What is the conversion of oral methadone to IV? Subscribe on iTunes , Android , or Stitcher Popular tertiary references suggest a conversion ratio of oral to IV methadone of 2:1, meaning 10 mg of oral methadone is equivalent to 5 mg of IV methadone. But a team of researchers recently published a scoping review on the bioavailability of methadone in the American Journal of Health-System Pharmacy that draws a different co

Inpatient 52

Inpatient 52

Drug Patent Watch

DECEMBER 17, 2023

VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,832,351 Expiration: Dec 19, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 17, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. However, the Court refused to issue an injunction removing the infringing product from the Canadian market, finding that it was not in the public interest to force patients to switch to another biosimilar product.

Biosimilars 52

Biosimilars Dosage 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

RX Note

DECEMBER 17, 2023

Introduction In an overview, Sale of Drugs Act 1952 and Control of Drugs and Cosmetics Regulations 1984 are legislations mainly discussing power and duties of few parties and manufacture of registered products or notified cosmetics. SODA - Sale of Drugs Act 1952 CDCR - Control of Drugs and Cosmetics Regulations 1984 DCA - Drug Control Authority Key Definitions "Drug" includes any substance, product or article intended to be used or capable, or purported or claimed to be capable, of being used on

Documentation 40

Documentation Labelling 40

Drug Patent Watch

DECEMBER 17, 2023

This chart shows the drug companies with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the… The post Which pharmaceutical companies have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59